Insulet Corp. Stock Drops After Omnipod 5 Insulin Leakage Defect Disclosure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy PODD?
Source: PRnewswire
- Stock Decline: Insulet Corp. shares fell approximately 6.9% following the March 12, 2026, 8-K filing that disclosed a design defect in the Omnipod 5 insulin pods, indicating investor concerns over the company's transparency.
- Defect Impact: The voluntary medical device correction affects about 1.5% of annual production, with the defect potentially causing insulin leakage that could lead to hospitalization and diabetic ketoacidosis (DKA), posing a serious health risk to patients.
- Serious Adverse Events: The defect is linked to eighteen serious adverse events, and the FDA's medical device correction database has cataloged this action, highlighting the severity of the issue and its potential impact on the company's reputation.
- Management Accountability Investigation: Levi & Korsinsky is investigating whether Insulet and its executives were aware of the defect during the February 18, 2026, earnings call, where the CEO described Omnipod as demonstrating “reliability and consistency,” contrasting sharply with the subsequent disclosure.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 208.220
Low
316.00
Averages
375.83
High
450.00
Current: 208.220
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Insulet Appoints New Chief Commercial Officer
- Executive Appointment: Insulet Corporation has appointed Mike Panos as Chief Commercial Officer, overseeing the global commercial organization and reporting directly to CEO Ashley McEvoy, aiming to enhance the company's commercial capabilities to seize market growth opportunities.
- Extensive Experience: Panos brings 30 years of commercial leadership experience in the medical technology sector, having held multiple senior roles at Stryker, where he successfully drove market expansion and sustained double-digit growth, which is expected to contribute strategically to Insulet's growth.
- Market Opportunity: Insulet is positioned for significant growth driven by strong clinical outcomes and customer-centric innovation, and Panos's leadership is anticipated to accelerate the adoption of automated insulin delivery globally, enhancing the company's market share in diabetes management.
- Strategic Execution: Panos will be responsible for driving commercial strategy and execution, expanding market access, and supporting growth into new patient populations, further solidifying Insulet's leadership position in the global diabetes management market.
See More
Stock Performance Comparison: DHR vs. PODD
- Stock Performance Comparison: DHR is currently trading up approximately 0.4%, while PODD is up about 1.6%, indicating differing market performances that could influence investor choices and market confidence.
- Market Dynamics Analysis: The midday trading on Thursday shows contrasting price movements for DHR and PODD, which may reflect varying investor perceptions tied to each company's business performance and market expectations.
- Investor Focus: The price changes of DHR and PODD could significantly impact investor decisions, especially in the context of increasing competition within the medical device sector, prompting investors to closely monitor upcoming financial reports and market trends.
- Industry Trend Impact: As the medical device industry continues to evolve, the stock fluctuations of DHR and PODD may be influenced by industry trends and technological innovations, necessitating that investors consider these factors for informed investment decisions.
See More
Insulet Corp. Stock Drops After Omnipod 5 Insulin Leakage Defect Disclosure
- Stock Decline: Insulet Corp. shares fell approximately 6.9% following the March 12, 2026, 8-K filing that disclosed a design defect in the Omnipod 5 insulin pods, indicating investor concerns over the company's transparency.
- Defect Impact: The voluntary medical device correction affects about 1.5% of annual production, with the defect potentially causing insulin leakage that could lead to hospitalization and diabetic ketoacidosis (DKA), posing a serious health risk to patients.
- Serious Adverse Events: The defect is linked to eighteen serious adverse events, and the FDA's medical device correction database has cataloged this action, highlighting the severity of the issue and its potential impact on the company's reputation.
- Management Accountability Investigation: Levi & Korsinsky is investigating whether Insulet and its executives were aware of the defect during the February 18, 2026, earnings call, where the CEO described Omnipod as demonstrating “reliability and consistency,” contrasting sharply with the subsequent disclosure.
See More
Insulet CEO Calls Omnipod 5 'Reliable' Before Voluntary Recall Announcement
- CEO Confidence and Recall: On February 18, 2026, Insulet CEO Ashley McEvoy described Omnipod 5 as 'reliable' and a 'favorite pump,' but just two weeks later, the company announced a voluntary recall of thousands of units due to insulin leakage defects, resulting in a 6.9% drop in stock price.
- Financial Performance and Market Demand: During the same earnings call, McEvoy highlighted strong demand for Omnipod 5 among type 1 and type 2 diabetes patients, which drove U.S. revenue growth above expectations, yet failed to mention any product quality issues, indicating a significant lapse in information disclosure.
- Medical Risks and Compliance Issues: The recall notice revealed that insulin leakage could lead to diabetic ketoacidosis, a serious medical emergency, underscoring potential risks to Insulet's product safety and possibly affecting future market trust.
- Shareholder Rights and Legal Action: Following the stock price decline, Insulet shareholders are encouraged to submit information to discuss their legal rights, reflecting strong investor concern regarding the management's transparency and accountability regarding product quality issues.
See More
Insulet Corporation Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Insulet Corporation, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Product Issue Disclosure: On March 12, 2026, Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through ongoing product monitoring, indicating potential deficiencies in the company's quality control.
- Stock Price Decline: Following this news, Insulet's stock price fell by $16.23, or 6.88%, closing at $219.84 on March 13, 2026, reflecting market concerns regarding the company's governance and product quality.
- Legal Context: Pomerantz LLP is a prominent securities class action law firm that has been fighting for investor rights for over 85 years, and unfavorable investigation outcomes could lead to substantial liability for Insulet.
See More
US Stocks Decline as Oil Prices Rebound Amid Middle East Tensions
- Market Weakness: The S&P 500 index fell by 0.61%, the Dow Jones Industrial Average dropped by 0.26%, and the Nasdaq 100 index decreased by 0.62%, reflecting investor concerns over Middle Eastern tensions that have driven stocks to 3.5-month lows.
- Oil Price Rebound: Crude oil prices surged over 3% as Iran escalated attacks in the Strait of Hormuz, which not only heightened inflation fears but also threatened global energy supply stability, impacting market confidence.
- Mixed Economic Data: January personal spending rose by 0.4%, surpassing expectations, while capital goods new orders remained unchanged, indicating economic recovery's fragility that could influence Federal Reserve policy decisions.
- Corporate Earnings Overview: With over 98% of S&P 500 companies reporting, 74% exceeded expectations, although overall earnings growth remains challenged, with Q4 earnings projected to rise by 8.4%, demonstrating market resilience amidst uncertainties.
See More
Insulet Appoints New Chief Commercial Officer
- Executive Appointment: Insulet Corporation has appointed Mike Panos as Chief Commercial Officer, overseeing the global commercial organization and reporting directly to CEO Ashley McEvoy, aiming to enhance the company's commercial capabilities to seize market growth opportunities.
- Extensive Experience: Panos brings 30 years of commercial leadership experience in the medical technology sector, having held multiple senior roles at Stryker, where he successfully drove market expansion and sustained double-digit growth, which is expected to contribute strategically to Insulet's growth.
- Market Opportunity: Insulet is positioned for significant growth driven by strong clinical outcomes and customer-centric innovation, and Panos's leadership is anticipated to accelerate the adoption of automated insulin delivery globally, enhancing the company's market share in diabetes management.
- Strategic Execution: Panos will be responsible for driving commercial strategy and execution, expanding market access, and supporting growth into new patient populations, further solidifying Insulet's leadership position in the global diabetes management market.
See More
Stock Performance Comparison: DHR vs. PODD
- Stock Performance Comparison: DHR is currently trading up approximately 0.4%, while PODD is up about 1.6%, indicating differing market performances that could influence investor choices and market confidence.
- Market Dynamics Analysis: The midday trading on Thursday shows contrasting price movements for DHR and PODD, which may reflect varying investor perceptions tied to each company's business performance and market expectations.
- Investor Focus: The price changes of DHR and PODD could significantly impact investor decisions, especially in the context of increasing competition within the medical device sector, prompting investors to closely monitor upcoming financial reports and market trends.
- Industry Trend Impact: As the medical device industry continues to evolve, the stock fluctuations of DHR and PODD may be influenced by industry trends and technological innovations, necessitating that investors consider these factors for informed investment decisions.
See More
Insulet Corp. Stock Drops After Omnipod 5 Insulin Leakage Defect Disclosure
- Stock Decline: Insulet Corp. shares fell approximately 6.9% following the March 12, 2026, 8-K filing that disclosed a design defect in the Omnipod 5 insulin pods, indicating investor concerns over the company's transparency.
- Defect Impact: The voluntary medical device correction affects about 1.5% of annual production, with the defect potentially causing insulin leakage that could lead to hospitalization and diabetic ketoacidosis (DKA), posing a serious health risk to patients.
- Serious Adverse Events: The defect is linked to eighteen serious adverse events, and the FDA's medical device correction database has cataloged this action, highlighting the severity of the issue and its potential impact on the company's reputation.
- Management Accountability Investigation: Levi & Korsinsky is investigating whether Insulet and its executives were aware of the defect during the February 18, 2026, earnings call, where the CEO described Omnipod as demonstrating “reliability and consistency,” contrasting sharply with the subsequent disclosure.
See More
Insulet CEO Calls Omnipod 5 'Reliable' Before Voluntary Recall Announcement
- CEO Confidence and Recall: On February 18, 2026, Insulet CEO Ashley McEvoy described Omnipod 5 as 'reliable' and a 'favorite pump,' but just two weeks later, the company announced a voluntary recall of thousands of units due to insulin leakage defects, resulting in a 6.9% drop in stock price.
- Financial Performance and Market Demand: During the same earnings call, McEvoy highlighted strong demand for Omnipod 5 among type 1 and type 2 diabetes patients, which drove U.S. revenue growth above expectations, yet failed to mention any product quality issues, indicating a significant lapse in information disclosure.
- Medical Risks and Compliance Issues: The recall notice revealed that insulin leakage could lead to diabetic ketoacidosis, a serious medical emergency, underscoring potential risks to Insulet's product safety and possibly affecting future market trust.
- Shareholder Rights and Legal Action: Following the stock price decline, Insulet shareholders are encouraged to submit information to discuss their legal rights, reflecting strong investor concern regarding the management's transparency and accountability regarding product quality issues.
See More
Insulet Corporation Under Investigation for Securities Fraud Claims
- Investigation Launched: Pomerantz LLP is investigating claims of securities fraud against Insulet Corporation, focusing on whether the company and its executives engaged in unlawful business practices that could harm investors.
- Product Issue Disclosure: On March 12, 2026, Insulet announced a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods after identifying a manufacturing issue through ongoing product monitoring, indicating potential deficiencies in the company's quality control.
- Stock Price Decline: Following this news, Insulet's stock price fell by $16.23, or 6.88%, closing at $219.84 on March 13, 2026, reflecting market concerns regarding the company's governance and product quality.
- Legal Context: Pomerantz LLP is a prominent securities class action law firm that has been fighting for investor rights for over 85 years, and unfavorable investigation outcomes could lead to substantial liability for Insulet.
See More
US Stocks Decline as Oil Prices Rebound Amid Middle East Tensions
- Market Weakness: The S&P 500 index fell by 0.61%, the Dow Jones Industrial Average dropped by 0.26%, and the Nasdaq 100 index decreased by 0.62%, reflecting investor concerns over Middle Eastern tensions that have driven stocks to 3.5-month lows.
- Oil Price Rebound: Crude oil prices surged over 3% as Iran escalated attacks in the Strait of Hormuz, which not only heightened inflation fears but also threatened global energy supply stability, impacting market confidence.
- Mixed Economic Data: January personal spending rose by 0.4%, surpassing expectations, while capital goods new orders remained unchanged, indicating economic recovery's fragility that could influence Federal Reserve policy decisions.
- Corporate Earnings Overview: With over 98% of S&P 500 companies reporting, 74% exceeded expectations, although overall earnings growth remains challenged, with Q4 earnings projected to rise by 8.4%, demonstrating market resilience amidst uncertainties.
See More
